Vanda Pharmaceuticals (VNDA)’ treatment of polycythemia vera was granted FDA orphan designation, according to a post to the agency’s website.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals Reports Strong Q3 2024 Growth
- Vanda Pharmaceuticals narrows 2024 revenue view to $190M-$210M from $180M-$210M
- Vanda Pharmaceuticals reports Q3 EPS (9c), consensus (16c)
- Wingstop upgraded, Estee Lauder downgraded: Wall Street’s top analyst calls
- Vanda Pharmaceuticals initiated with a Buy at H.C. Wainwright